Lacerta Therapeutics

About:

Lacerta Therapeutics is a clinical stage gene therapy company.

Website: http://www.lacertatherapeutics.com/

Twitter/X: lacertatxaav

Top Investors: Sarepta Therapeutics

Description:

Lacerta Therapeutics is a clinical stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases. With unmatched scientific expertise and depth in the development, production, and application of AAV vectors, Lacerta Therapeutics is advancing its clinical programs using its proprietary capsid variants and scalable vector manufacturing platform. The experience and accomplishments of the Lacerta Therapeutics founders are unsurpassed in AAV gene therapy. In addition to world-class basic AAV vector development and gene therapy clinical trial expertise, our team brings to bear individuals with novel insight into developing novel, targeted neurological and lysosomal storage disease treatments.

Total Funding Amount:

$30M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Alachua, Florida, United States

Founded Date:

2017-01-01

Contact Email:

info(AT)lacertatherapeutics.com

Founders:

Arun Srivastava, Coy Heldermon, Edgar Rodriguez-Lebron, Kenneth Warrington, Nicholas Muzyczka, Ronald Mandel, Sergei Zolotukhin, Todd E. Golde

Number of Employees:

11-50

Last Funding Date:

2018-08-09

IPO Status:

Private

Industries:

© 2025 bioDAO.ai